Test Declared One of the Most Pioneering Healthcare Innovations in 21st
AMSTERDAM, Netherlands, June 26 /PRNewswire/ -- Agendia BV, a world leader in gene expression analysis-based diagnostics, is pleased to announce that the company recently received a prestigious award for its groundbreaking MammaPrint(R) test from the Dutch Innovation Platform. MammaPrint, a 70-gene signature diagnostic test that predicts high or low risk of breast cancer tumor recurrence, was chosen out of more than 150 entries as the most pioneering healthcare initiative and will have the distinguished honor of being actively supported at a national level by the Dutch government.
"We are honored that the value of MammaPrint has been recognized at a governmental level for its significant impact on the management of breast cancer," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This award provides us with the national support that will ensure that even more breast cancer patients will benefit from personalized treatment."
MammaPrint was among four healthcare innovations awarded by Dutch Health Minister Ab Klink, chairman of the Healthcare Innovation Platform, at a recent Netherlands-based Healthcare summit. The Innovation Platform is the government's initiative dedicated to advancing The Netherlands toward becoming one of the top five international countries in the areas of higher education, research and innovation by creating the conditions, establishing the connections, and developing the vision required to stimulate innovation and entrepreneurship.
"Each year, more than 13,000 women are diagnosed with breast cancer in The Netherlands, with another 317,000 diagnosed throughout Europe and nearly 180,000 diagnosed in the United States," said Richard Bender, MD, FACP, Agendia's chief medical officer. "At Agendia, we are committed to making a positive impact on the health and quality of life of people suffering from cancer, and new technologies like MammaPrint are changing the way oncologists are treating this life-threatening disease in a way that directly benefits patients' lives."
As part of the recognition and support surrounding the award, Minister Klink noted that he would actively support the inclusion of MammaPrint in the package of treatments for which reimbursement is available so that the test can provide benefit to as many breast cancer patients as possible in The Netherlands.
MammaPrint laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint tests are conducted in Agendia's CLIA-certified central service laboratory.
Agendia, located in Amsterdam, The Netherlands, is a world leader in
gene expression analysis-based diagnostics with three products on the
market. The company focuses on the development and commercialization of
diagnostic tests using tumor gene expression profiling. Agendia was the
first company to commercialize a prognostic test - MammaPrint(R) - that
predicts the risk of breast cancer recurrence. Agendia maintains close ties
with several leading academic centers to develop state of the art
diagnostic tests for cancer. Agendia also offers its expertise to pharma
companies focusing on development of highly effective personalized drugs in
the area of oncology. For more information on Agendia, please visit
* CupPrint(R) is based on a license to the TUO database of AviaraDx
For Agendia - EU & non-U.S.-based Media:
Dr. Bernhard Sixt
President and Chief Executive Officer
For Agendia - U.S. Media:
Ogilvy Public Relations Worldwide
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved